Advertisement
Advertisement
TWST
Twist Bioscience Corporation Common Stock
148.76
USDSponsored
-24.69
-14.23%
Oct 30, 14:23 UTC -4
Open
Twist Bioscience Corporation Common Stock (TWST) Earnings
TWST Earnings Reports
Positive Surprise Ratio
TWST beat 18 of 32 last estimates.
56%
Next Report
Date of Next Report
Nov 12, 2026
Estimate for Q4 26 (Revenue/ EPS)
$125.03M
/-$0.37
Implied change from Q3 26 (Revenue/ EPS)
+5.62%
/-33.93%
Implied change from Q4 25 (Revenue/ EPS)
+26.28%
/-17.78%
Twist Bioscience Corporation Common Stock earnings per share and revenue
On Aug 03, 2026, TWST reported earnings of -0.56 USD per share (EPS) for Q3 26, missing the estimate of -0.50 USD, resulting in a -11.20% surprise. Revenue reached 118.38 million, compared to an expected 116.78 million, with a 1.37% difference. The market reacted with a +10.39% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 11 analysts forecast an EPS of -0.37 USD, with revenue projected to reach 125.03 million USD, implying an decrease of -33.93% EPS, and increase of 5.62% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
PTC Therapeutics, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.34
Actual
$0.61
Surprise
+75.59%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
FAQ
What were Twist Bioscience Corporation Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Twist Bioscience Corporation Common Stock reported EPS of -$0.56, missing estimates by -11.2%, and revenue of $118.38M, 1.37% above expectations.
How did the market react to Twist Bioscience Corporation Common Stock's Q3 2026 earnings?
The stock price moved up 10.39%, changed from $91.55 before the earnings release to $101.06 the day after.
When is Twist Bioscience Corporation Common Stock expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for Twist Bioscience Corporation Common Stock's next earnings report?
Based on 11
analysts, Twist Bioscience Corporation Common Stock is expected to report EPS of -$0.37 and revenue of $125.03M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.